lpca Laboratories Ltd. (lpca) has embarked on a collaboration with Omexa Formulary Pvt. Ltd. (Omexa), through a Technology Transfer Agreement aimed at fostering the development of an anti-cancer biosimilar for the global market. This strategic partnership grants Omexa non-exclusive rights to research, develop, manufacture, and market the biosimilar, marking a significant step in the fight against cancer.

The agreement between lpca and Omexa is set to enhance Omexa’s biosimilar development capabilities, from the initial stages of development through to clinical trials and ultimately, the commercial launch. This collaboration underscores both companies’ commitment to advancing healthcare solutions and addresses a critical need for affordable and effective biologic medications in the treatment of chronic illnesses worldwide.

Mr. Pranay Godha, Managing Director and CEO of lpca Laboratories, expressed enthusiasm about the partnership, highlighting its potential to empower Omexa with a robust foundation for anti-cancer and anti-inflammatory monoclonal antibody product development. “This collaboration with Omexa Formulary, an innovation-driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development,” stated Godha. He further emphasized lpca’s commitment to developing high-quality, affordable biosimilars that meet global standards and contribute significantly to combating chronic diseases.

Dr. Nate Ramanathan, Managing Director & CEO of Omexa Formulary, also commented on the significance of this alliance, noting that it leverages lpca’s reliability and expertise in pharmaceutical development. “This collaboration with lpca, a most reliable and trusted pharmaceutical company, shall facilitate Omexa the availability of expertise and technology for the biosimilars development work,” said Ramanathan. He highlighted Omexa’s dedication to making quality biologic drugs accessible and affordable to a broader population, aligning with the company’s core values and innovative approaches in research and manufacturing.

This partnership represents a pivotal moment in the pharmaceutical industry, setting a new benchmark for the development of biosimilars and the provision of life-saving treatments at a global scale. By combining their strengths, lpca Laboratories and Omexa Formulary are poised to make significant strides in addressing the unmet needs of patients around the world, particularly those battling cancer.

  anti-cancer biosimilar, biologic medication, global health, lpca Laboratories, monoclonal antibody development, Omexa Formulary, pharmaceutical collaboration, technology transfer agreement